Back to top
more

Adaptive Biotechnologies (ADPT)

(Real Time Quote from BATS)

$4.03 USD

4.03
455,930

-0.01 (-0.25%)

Updated Jul 22, 2024 01:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ADPT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Adaptive Biotechnologies Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 346 498 353 688 577
Receivables 38 40 17 10 13
Notes Receivable 0 0 0 0 0
Inventories 14 14 19 14 9
Other Current Assets 11 9 13 15 14
Total Current Assets 410 562 403 727 613
Net Property & Equipment 68 83 85 40 60
Investments & Advances 0 0 217 119 105
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 124 126 128 129 131
Deposits & Other Assets 7 4 3 3 3
Total Assets 661 857 923 1,116 912
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 8 8 3 3 4
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 22 28 25 25 13
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 49 64 80 73 61
Total Current Liabilities 88 110 114 105 78
Mortgages 0 0 0 0 0
Deferred Taxes/Income 45 59 99 164 226
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 37
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 131 125 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 353 393 319 373 341
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,453 1,387 1,324 1,254 936
Retained Earnings -1,144 -919 -719 -512 -365
Other Equity 0 -4 -1 1 1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 308 464 604 743 571
Total Liabilities & Shareholder's Equity 661 857 923 1,116 912
Total Common Equity 308 464 604 743 571
Shares Outstanding 144.70 143.00 141.10 136.70 124.30
Book Value Per Share 2.13 3.25 4.28 5.44 4.59

Fiscal Year End for Adaptive Biotechnologies Corporation falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 309 346 371 417
Receivables NA 42 38 31 32
Notes Receivable NA 0 0 0 0
Inventories NA 13 14 19 19
Other Current Assets NA 10 11 13 9
Total Current Assets NA 374 410 435 477
Net Property & Equipment NA 65 68 77 79
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 124 124 125 125
Deposits & Other Assets NA 6 7 6 6
Total Assets NA 620 661 718 765
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 12 8 4 9
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 14 22 21 19
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 47 49 59 58
Total Current Liabilities NA 83 88 93 95
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 44 45 44 51
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 131 127 128
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 346 353 356 369
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,467 1,453 1,437 1,422
Retained Earnings NA -1,192 -1,144 -1,075 -1,025
Other Equity NA 0 0 0 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 275 308 362 396
Total Liabilities & Shareholder's Equity NA 620 661 718 765
Total Common Equity 0 275 308 362 396
Shares Outstanding 147.30 147.30 144.70 144.60 144.60
Book Value Per Share 0.00 1.87 2.13 2.50 2.74